CLINICAL ASPECTS OF LOW-GRADE SQUAMOUS INTRAEPITHELIAL LESIONS


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The paper gives an update on the diagnosis and management of women with human papillomavirus (HPV)-associated genital diseases and low- and high-grade squamous intraepithelial lesions (LSIL, HSIL). The management of the latter continues to be ambiguous, is constantly being improved by evidence-based studies, and involves ablation and excision and the observational tactic without destructive interventions is justified. LSIL is a particular problem since the majority of its histologically verified cases regress spontaneously and less than 1% gives rise to invasive carcinoma. No specific drugs that completely eliminate HPV have been designed today, but investigations of alternative antiviral and immunomodulatory agents are being continued. Isoprinosine (inosine pranobex) is one of the most tested immune system activators. The data of trials dealing with the use of various drugs are presented.

Full Text

Restricted Access

About the authors

S. I ROGOVSKAYA

Russian Medical Academy of Postgraduate Education

Email: srogovskaya@mail.ru

L. I TEREBNEVA

Russian Medical Academy of Postgraduate Education

References

  1. Кедрова А.Г., Подистов Ю.И., Кузнецов В.В., Брюзгин В.В., Козаченко В.П., Никогосян С.О. Роль противовирусной терапии в комплексном лечении больных эпителиальными дисплазиями и преинвазивным раком шейки матки. Гинекология. 2005; 7(3): 170-4.
  2. Stanley M. Chapter 17: Genital human papillomavirus infections--current and prospective therapies. J. Natl. Cancer Inst. Monogr. 2003; (31): 117-24.
  3. World Health Organization (WHO). Comprehensive Cervical Cancer Control. A guide to essential practice. Geneva: WHO; 2006.
  4. Wright T.C. Jr., Massad L.S., Dunton C.J., Spitzer M., Wilkinson E.J., Solomon D.; 2006 American Society for Colposcopy and Cervical Pathology-sponsored Consensus Conference. Consensus guidelines for management of women with CIN and AIS. Am. J. Obstet. Gynecol. 2007; 197(4): 340-5.
  5. Подзолкова Н.М., Роговская С.И., Фадеев И.Е., Ардус Ф.С. Папилломавирусная инфекция: что нового? Гинекология. 2011; 13(5): 39-45.
  6. Сухих Г.Т., Прилепская В.Н., Роговская С.И., Бебнева Т.Н., Межевитинова Е.А., Петрунин Д.Д. Применение препаратов интерферона при лечении плоскоклеточных поражений шейки матки низкой степени. З турботою про жінку (Київ). 2012; 8(38): 10-2.
  7. Arbyn M., Anttila A., Jordan J., Ronco G., Schenck U., Segnan N. et al., eds. European European guidelines for quality assurance in cervical cancer screening. 2nd ed. Luxembourg: Office for Official Publications of the European Communities; 2008. 291p.
  8. Jordan J., Martin-Hirsch P., Arbyn M., Schenck U., Baldauf J.-J., D. Da Silva D. et al. European guidelines for clinical management of abnormal cervical cytology. Part 2. Cytopathology. 2009; 20(1): 5—16.
  9. HPV treatment guidlines. www.cdc.govstdtreatment6-2010
  10. Spitzer M. Screening and management of women and girls with human papillomavirus infection. Gynecol. Oncol. 2007; 107(2, Suppl.1): S14-8.
  11. Минкина Г.Н., Калинина В.С., Гаврикова М.В., Храмова О.К., Фириченко С.В. Постлечебный мониторинг цервикальных интраэпителиальных неоплазий. Журнал акушерства и женских болезней. 2011; 1: 109-13.
  12. ASCUS-LSIL Traige Study (ALTS) Group. A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. Am. J. Obstet. Gynecol. 2003; 188(6): 1393—400.
  13. Подзолкова Н.М., Роговская С.И., Минкина Г.Н., Короденкова Л.И., Акопова Е.С. Новое в кольпоскопии. Гинекология. 2011; 13(6): 20-5.
  14. Киселев В.И., Киселев О.И., Северин Е.С. Исследование специфической активности индол-3-карбинола в отношении клеток, инфицированных вирусом папилломы человека. Вопросы биологической, медицинской и фармацевтической химии. 2003; 4: 28-32.
  15. Machado F.A., Janssens J.P., Michelin M.A., Murta E.F. Immune response and immunotherapy in intraepithelial and invasive lesions of the uterine cervix. Clin. Exp. Obstet. Gynecol. 2012; 39(1): 27-31.
  16. Сухих Г.Т., Прилепская В.Н., Роговская С.И., Бебнева Т.Н., Межевитинова Е.А., Петрунин Д.Д. Применение препаратов интерферона при лечении плоскоклеточных поражений шейки матки низкой степени. З турботою про жінку (Київ). 2012; 8(38): 10-2.
  17. Frega A., Stentella P., De Ioris A., Piazze J.J., Fambrini M., Marchionni M., Cosmi E. V. Young women, cervical intraepithelial neoplasia and human papillomavirus: risk factors for persistence and recurrence. Cancer Lett. 2003; 196(2): 127-34.
  18. Seresini S., Origoni M., Lillo F., Caputo L., Paganoni A.M., Vantini S. et al. IFN-gamma produced by human papilloma virus-18 E6-specific CD4+ T cells predicts the clinical outcome after surgery in patients with high-grade cervical lesions. J. Immunol. 2007; 179(10): 7176-83.
  19. Visser J., Nijman H.W., Hoogenboom B.N., Jager P., van Baarle D., Schuuring E. et al. Frequencies and role of regulatory T cells in patients with (pre)malignant cervical neoplasia. Clin. Exp. Immunol. 2007; 150(2): 199-209.
  20. Russomano F., Reis A., de Camargo M., Dutra M.V., Fonseca S.C., Anderson J. Efficacy in treatment of subclinical cervical HPV infections without CIN. Systemic review. Sao Paulo Med. J. 2000; 118(4): 109-15.
  21. Дубенский В.В., Кузнецов В.П., Беляев Д.Л., Слюсарь Н.Н. Эффективность иммунокоррекции цитокинами при лечении папилломавирусной инфекции. Журнал микробиологии, эпидемиологии и иммунобиологии. 2001; 5: 54-8.
  22. Verguts J., Bronselaer B., Donders G., Arbyn M., Van Eldere J., Drijkoningen M. et al. The diagnosis and therapy of HPV-associated genital lesions: the role of systemic beta-interferon treatment. Minerva Ginecol. 1995; 47(1-2): 31-7.
  23. Grimm C., Polterauer S., Natter C., Rahhal J., Hefler L., Tempfer C.B. et al. Treatment of cervical intraepithelial neoplasia with topical imiquimod: a randomized controlled trial. Obstet. Gynecol. 2012; 120(1): 152-9.
  24. Bornstein J., Pascal B., Zarfati D., Goldshmid N., Abramovici H. Recombinant human interferon-β for condylomata acuminata: a randomized, double-blind, placebo-controlled study of intralesional therapy. Int. J. STD AIDS. 1997; 8(10): 614-21.
  25. Iljazović E., Ljuca D., Sahimpasić A., Avdić S. Efficacy in treatment of cervical HRHPV infection by combination of beta interferon, and herbal therapy in woman with different cervical lesions. Bosn. J. Basic Med. Sci. 2006; 6(4): 79-84.
  26. Herdman M.T., Pett M.R., Roberts I., Alazawi W.O., Teschendorff A.E., Zhang X.Y. et al. Interferon-beta treatment of cervical keratinocytes naturally infected with human papillomavirus 16 episomes promotes rapid reduction in episome numbers and emergence of latent integrants. Carcinogenesis. 2006; 27(11): 2341-53.
  27. Роговская С.И., Акопова Е.С., Коган Е.А. Совершенствование лечебно-диагностических подходов к ВПЧ-инфекции гениталий. Русский медицинский журнал. 2011; 20: 1238-43.
  28. Schofer H., Van Ophoven A., Henke U., Lenz T., Eul A. Randomized, comparative trial on the sustained efficacy of topical imiquimod 5% cream versus conventional ablative methods in external anogenital warts. Eur. J. Dermatol. 2006; 16(6): 642-8.
  29. Syed T.A., Ahmadpour O.A. Human leukocyte derived interferon- alpha in a hydrophilic gel for the treatment of intravaginal warts in women: a placebo-controlled, double-blind study. Int. J. STD AIDS. 1998; 9(12): 769-72.
  30. Елисеева М.Ю., Мынбаев О.А. Вспомогательная иммунотерапия ВПЧ-ассоциированных поражений слизистых оболочек и кожи урогенитальной и перианальной локализации. Гинекология. 2007; 11(5): 22-33.
  31. Прилепская В.Н., Роговская С.И. Возможности Изопринозина в лечении хронических цервицитов и вагинитов. Русский медицинский журнал. 2008; 16(1): 5-9.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies